Cogent Biosciences (COGT) traded lower on Wednesday, April 29, 2026, with the decline aligning with a supply-overhang narrative after a recent Form 144 disclosed a proposed sale of up to 7.0 million shares tied to a March 31, 2026 conversion of Series A convertible preferred stock. A Form 144 is a notice of a potential sale under Rule 144 and can weigh on biotech stocks by signaling additional stock may hit the market, even if the shares are not ultimately sold. (stocktitan.net)

The proposed 7.0 million-share sale is large enough to matter for short-term trading dynamics because it can increase perceived near-term supply and encourage risk-off positioning among momentum holders. With COGT near the upper end of its 52-week range, traders often react quickly to any sign of incremental selling pressure. (marketbeat.com)

The dip is occurring against a backdrop of recent bezuclastinib regulatory progress. On April 1, 2026, Cogent announced submission of an NDA for bezuclastinib in gastrointestinal stromal tumors (GIST) under the FDA’s RTOR program, and the company’s NonAdvSM NDA has a PDUFA target action date of December 30, 2026—keeping multiple 2026 catalysts in view even as the market focuses on potential near-term supply. (stocktitan.net)

Investors will be watching for any evidence the proposed selling turns into executed sales (or fades without follow-through), as well as updates around bezuclastinib’s regulatory timelines and upcoming data presentations. If trading volume picks up alongside continued weakness, the market may be signaling that the overhang is being actively priced in; if volume remains muted, the move may reflect caution rather than confirmed distribution.